Phase Ib Study of BI 836880 (VEGF/Ang2 nanobody) in Combination With Ezabenlimab (anti–PD-1 antibody) in Patients With Advanced or Metastatic Solid Tumors From December 2022 to January 2025, one MRT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results